Overcoming antigen loss in CAR T therapy with Vγ9Vδ2 CAR T-cells
Background: Vγ9Vδ2 T-cells demonstrate potent antitumor activity in vitro but, despite successful safety studies, the clinical benefit of Vγ9Vδ2 in adoptive cell therapy has been limited. One approach to enhance the therapeutic potential of Vγ9Vδ2 T-cells while maintaining their safety profile is ge...
Saved in:
| Main Authors: | M. Velasco Santiago, P. Aehnlich, T.M. Hulen, K.M. Jensen, G. Holmen Olofsson, Ö. Met, P. thor Straten |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Immuno-Oncology and Technology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590018825000139 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
From ex vivo to in vitro models: towards a novel approach to investigate the efficacy of immunotherapies on exhausted Vγ9Vδ2 T cells?
by: Morgane Chauvet, et al.
Published: (2025-04-01) -
An organotypic human melanoma-in-skin model as an in vitro tool for testing Vγ9Vδ2-T cell-based immunotherapy
by: E. Michielon, et al.
Published: (2024-12-01) -
Vγ9Vδ2 T cells expanded with vitamin C combined with HMBPP in vitro inhibit intracellular Mycobacterium tuberculosis growth
by: Shuyan Liu, et al.
Published: (2025-04-01) -
Recognition of MR1-antigen complexes by TCR Vγ9Vδ2
by: José Pedro Loureiro, et al.
Published: (2025-02-01) -
Autologous Peripheral Vγ9Vδ2 T Cell Synergizes with αβ T Cell Through Antigen Presentation and BTN3A1 Blockade in Immunotherapy of Cervical Cancer
by: Min Wu, et al.
Published: (2025-05-01)